Jeffrey A Allen

Emailjaallenumnedu

Research activity per year

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

Fingerprint

The Fingerprint is created by mining the titles and abstracts of the person's research outputs and projects/funding awards to create an index of weighted terms from discipline-specific thesauri.

1 Similar Profiles

7 Finished
8 Active

A Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with Generalized Myasthenia Gravis (gMG)
Allen, J. A. (PI)
IMMUNOVANT, INC
7/1/23 → 6/30/28
Project: Research project
A Long-term Extension of the ARGX-117-2002 Trial to Evaluate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy
Allen, J. A. (PI)
ARGENX
9/1/22 → 8/31/28
Project: Research project
Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Subcutaneously Administered Efgartigimod with rHuPH20in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Allen, J. A. (PI)
ARGENX
6/1/22 → 5/31/27
Project: Research project
A Phase 2, multicenter, open-label, non-randomized, proof-of-concept study evaluating the efficacy, safety, and tolerability of BIVV020 in adults with chronic inflammatory demyelinating polyneuropathy (CIDP)
Allen, J. A. (PI)
SANOFI-AVENTIS US
1/1/22 → 12/31/27
Project: Research project
A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifoca
Allen, J. A. (PI)
PPD INVESTIGATOR SERVICES, LLC, ARGENX
10/1/21 → 9/30/25
Project: Research project

41 Article
11 Review article
4 Chapter
4 Editorial
More
- 2 Letter
- 1 Comment/debate

Lenalidomide in the treatment of anti-myelin-associated glycoprotein neuropathy: A phase 1 study to identify the maximum tolerated dose
Stino, A. M., Bumma, N., Smith, R., Davalos, L., Allen, J., Ye, J. C., Pianko, M., Campagnaro, E., Fierro, C., Awad, A., Murdock, B., Pietrzak, M., Loszanski, G., Kline, D. M., Efebera, Y. & Elsheikh, B., Mar 2024, In: European Journal of Neurology. 31, 3, e16164.
Research output: Contribution to journal › Article › peer-review

Open Access
Subcutaneous batoclimab in generalized myasthenia gravis: Results from a Phase 2a trial with an open-label extension
Nowak, R. J., Breiner, A., Bril, V., Allen, J. A., Khan, S., Levine, T., Jacobs, D. H., Sahagian, G., Siddiqi, Z. A., Xu, J., Macias, W. L. & Benatar, M., Jan 2024, In: Annals of Clinical and Translational Neurology. 11, 1, p. 194-206 13 p.
Research output: Contribution to journal › Article › peer-review

Open Access
3 Scopus citations
Anti–myelin-associated glycoprotein neuropathy: Where do we stand?
Stino, A. M., Elsheikh, B. & Allen, J. A., Nov 2023, In: Muscle and Nerve. 68, 6, p. 823-832 10 p.
Research output: Contribution to journal › Review article › peer-review

Open Access
1 Scopus citations
CIDP prognosis in patients with IVIG treatment-related fluctuations
Cook, M., Pasnoor, M., Ajroud-Driss, S., Brannagan, T. H., Dimachkie, M. M. & Allen, J. A., Jan 2023, In: Muscle and Nerve. 67, 1, p. 69-73 5 p.
Research output: Contribution to journal › Article › peer-review

Open Access
3 Scopus citations
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study
RAISE Study Team, May 2023, In: The Lancet Neurology. 22, 5, p. 395-406 12 p.
Research output: Contribution to journal › Article › peer-review
70 Scopus citations

Jeffrey A Allen

Personal profile

Expertise related to UN Sustainable Development Goals

Fingerprint

Collaborations and top research areas from the last five years

Dive into details

A Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with Generalized Myasthenia Gravis (gMG)

A Long-term Extension of the ARGX-117-2002 Trial to Evaluate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy

Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Subcutaneously Administered Efgartigimod with rHuPH20in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

A Phase 2, multicenter, open-label, non-randomized, proof-of-concept study evaluating the efficacy, safety, and tolerability of BIVV020 in adults with chronic inflammatory demyelinating polyneuropathy (CIDP)

A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifoca

Lenalidomide in the treatment of anti-myelin-associated glycoprotein neuropathy: A phase 1 study to identify the maximum tolerated dose

Subcutaneous batoclimab in generalized myasthenia gravis: Results from a Phase 2a trial with an open-label extension

Anti–myelin-associated glycoprotein neuropathy: Where do we stand?

CIDP prognosis in patients with IVIG treatment-related fluctuations

Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study

Jeffrey A Allen

Personal profile

Expertise related to UN Sustainable Development Goals

Fingerprint

Collaborations and top research areas from the last five years

Projects

Research output